Skip to main content

Kenvue earnings top estimates in J&J spinoff's first quarterly report since IPO

J&J still owns a 90% stake in Kenvue, meaning it can generally control the direction of the consumer health spinoff’s business for the time being.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.